Oftalmol Zh.2011;6:8-12.

 Full text Pdf 


http://doi.org/10.31288/oftalmolzh20116812

THE ANALYSIS OF THE CAUSES OF DEVELOPMENT OF POSTVITRECTOMY VITREOUS HEMORRHAGE IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY

Pogorelyi D. N., Putienko A. A.

Odessa, Ukraine

There were performed comparative analyses of two groups of patients with proliferative diabetic retinopathy. The main group consisted of 68 patients (68 eyes) who had recurrence of vitreous hemorrhage during 2-2.5 month after vitrectomy and the control group — 75 patients (75 eyes) who had transparent content of the vitreous cavity in the same period of time after surgery. Hemorrhage statistically developed more often in cases of diabetes of I type (%2=7.46, p=0.006), hypoglycemia, mainly at night (%2=8.48, p=0.004), increase of the arterial pressure (%2=7.40, p = 0.007), presence of total vitreous hemorrhage before the operation (%2=5.86, p=0.016), recurrences of vitreous hemorrhage within 6 months before the operation (%2=6.68, p=0.009), development of intraoperative bleedings (X2=7.67, p=0.006), development of hyphema (%2=4.71; p=0.03) with necessity of its washing in early period after the operation (%2 = 4.95, p = 0.026) as well as development of exudative reactions in the early postoperative period (%2=5.76; p=0.016), accompanied with elevation of intraocular pressure (%2=9,35, p=0.002).

 

References

1.Avitabile T.  Severe proliferative diabetic retinopathy treated with vitrectomy or panretinal photocoagulation: a monocenter randomized controlled clinical trial /T. Avitabile, V. Bonfiglio, F Castiglione // Can J. Ophthalmol. — 2011. — V.46. — № 4. — Р.345- 351.
Crossref

2.Entezari M. Cryotherapy of sclerotomy sites for prevention of late post-vitrectomy diabetic hemorrhage: a randomized clinical trial / M. Entezari, A. Ramezani, H. Ahmadieh // Graefes. Arch Clin Exp Ophthalmol. — 2010. — № 248. — Р. 1-19.}
Crossref

3.Gunduz K. Management of proliferative diabetic retinopathy / K. Gunduz, S. J. Bakri // Compr. Ophthalmol Update. — 2007. — V.8. — № 5. — р. 245- 256.

4.Neely K. A. Peripheral retinal cryotherapy for postvitrectomy diabetic vitreous hemorrhage in phakic eyes / K. A. Neely, M. W. Scroggs, B. W. McCuen // Am. J. Ophthalmol. — 1998. — № 126. — V.1. — Р. 82- 90.
Crossref

5.Rizzo S. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR) / S. Rizzo, F Genovesi-Ebert, E. Di Bartolo et al. // Graefes. Arch Clin Exp Ophthalmol. — 2008. — № 246. — Р.837- 842.
Crossref

6.Romano M. R. Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? M. R. Romano, S. K. Gibran, J. Marticorena et al. // Eye. — 2009. — V. 23. — № 8. — Р.1698- 1701.
Crossref

7.Yang C. M. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy / C. M. Yang, P. T. Yeh, C. H. Yang // Ophthalmology. — 2007. — V.114. — № 4. — Р. 710-715.
Crossref

8.West J. F. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy / J. F. West, Z. J. Gregor // Br. J Ophthalmol. — 2000. — № 84. — Р. 822- 825.
Crossref

9.Wu W. C. Management of postvitrectomy diabetic vitreous hemorrhage with volume homeostatic fluid-fluid exchanger / W. C. Wu, J. Y. Chen, Y. C. Chen // Graefes Arch Clin Exp Ophthalmol.  2009. — V.247. — № 9. — Р.1183- 1189.
Crossref